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Essentials of ﬁ loviral load quantiﬁ cation
Lieselotte Cnops, Johan van Griensven, Anna N Honko, Daniel G Bausch, Armand Sprecher, Charles E Hill, Robert Colebunders, Joshua C Johnson, 
Anthony Griﬃ  ths, Gustavo F Palacios, Colleen S Kraft, Gary Kobinger, Angela Hewlett, David A Norwood, Pardis Sabeti, Peter B Jahrling, 
Pierre Formenty, Jens H Kuhn*, Kevin K Ariën*
Quantitative measurement of viral load is an important parameter in the management of ﬁ lovirus disease outbreaks 
because viral load correlates with severity of disease, survival, and infectivity. During the ongoing Ebola virus disease 
outbreak in parts of Western Africa, most assays used in the detection of Ebola virus disease by more than 44 
diagnostic laboratories yielded qualitative results. Regulatory hurdles involved in validating quantitative assays and 
the urgent need for a rapid Ebola virus disease diagnosis precluded development of validated quantitative assays 
during the outbreak. Because of sparse quantitative data obtained from these outbreaks, opportunities for study of 
correlations between patient outcome, changes in viral load during the course of an outbreak, disease course in 
asymptomatic individuals, and the potential for virus transmission between infected patients and contacts have been 
limited. We strongly urge the continued development of quantitative viral load assays to carefully evaluate these 
parameters in future outbreaks of ﬁ lovirus disease.
Introduction
The mononegaviral family Filoviridae currently has eight 
members, six of which are known to cause human 
disease. Of these six, the two marburgviruses, Marburg 
virus and Ravn virus, cause Marburg virus disease 
(International Classiﬁ cation of Diseases-10 [ICD-10] 
A98.3); and four ebolaviruses, Bundibugyo virus, Ebola 
virus, Sudan virus, and Taï Forest virus, cause Ebola 
virus disease (ICD-10 A98.4).1 Patients typically present 
with a range of non-speciﬁ c signs and symptoms, 
including fever, headache, weak ness, malaise, myalgia, 
conjunctival injection, gastro intestinal disturbances (eg, 
abdominal pain, nausea, vomiting, and diarrhoea), and, 
less frequently, bleeding.1 Marburg virus disease and 
Ebola virus disease are impossible to diﬀ erentiate from 
each other on the basis of clinical observation alone.2 In 
the early phases of disease and in the absence of a 
recognised outbreak, readily distinguishing ﬁ lovirus 
disease from a host of more common causes of systemic 
febrile disease—for example malaria, typhoid fever, 
bacterial gastroenteritis, and other viral haemorrhagic 
fevers such as severe dengue or Lassa fever—is very 
diﬃ  cult.1 Thus, rapid and safe laboratory diagnosis of 
patients with suspected Marburg virus disease and Ebola 
virus disease is imperative, and should not rely on 
ﬁ lovirus culture, which requires specialised biosafety 
level 4 facilities.
In recent years, the development of ﬁ eld-deployable 
molecular assays, especially RT-PCR, for the diagnosis 
of ﬁ lovirus infection has proved to be an invaluable tool 
for case identiﬁ cation and management, and for general 
outbreak control. At the peak of the massive and ongoing 
outbreak of Ebola virus disease in Western Africa, more 
than 44 laboratories provided such diagnostic services.3 
Serological tests are not particularly useful in diagnosing 
acute ﬁ lovirus infection, since the presence of IgG might 
mean little in a ﬁ lovirus-endemic area and IgM can 
represent diﬀ erent stages of ﬁ loviral disease. Therefore, 
diagnosing recent ﬁ lovirus infection might require 
sequential blood draws to ascertain increasing IgM 
titres.4 Several rapid antigen detection tests (RDTs) have 
been developed, such as ReEBOV, SD Q Line, and 
OraQuick.5–7 However, RDTs have low sensitivity and 
speciﬁ city. Additionally, results obtained with RDTs still 
require conﬁ rmation by PCR, and at best are semi-
quantitative. Nucleic acid detection is thus the most 
common procedure for diagnosing viral diseases, 
including ﬁ lovirus disease, because of its unsurpassed 
speciﬁ city and sensitivity, and its ability to detect acute 
infection. Additionally, the virus does not need to be 
viable at the time of testing.8
Importance of ﬁ lovirus load determination
Real-time RT-PCR provides not only a qualitative 
diagnosis, but also a surrogate measure of the virus 
burden in a sample by determining the cycle threshold, 
which varies inversely with viral load. Measurement of 
viral load is an important parameter in Marburg virus 
disease and Ebola virus disease, because viral load 
correlates with severity of disease, survival, and 
infectivity.9–16 Assessing the viral load, and thus the 
potential infectivity of a patient, can guide triage and 
admission placement to minimise risk of interperson 
trans mission. Viral load measurements are also 
important to better understand the clinical presentation 
and pathogenesis of ﬁ lovirus disease, and to interpret the 
eﬃ  cacy of candidate therapies and vaccines in animal 
models and human beings.17–19 For instance, the interim 
analysis of a favipiravir mono therapy trial in Guinea 
revealed that the product might be eﬃ  cacious against 
Ebola virus when the cycle threshold is 20 or higher, but 
not when it is less than 20.20 For the ﬁ nal analysis, Sissoko 
and colleagues retested all samples with quantitative 
RT-PCR in a reference laboratory in France. Although the 
investigators observed a good correlation between cycle 
threshold values and RNA viral loads, they pointed out 
that the measured cycle threshold values might not be 
universally replicable, because they could vary depending 
on technique and technician experience, and that more 
robust standards are required.21
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The extent of viral load might be the key factor 
explaining the large variation in lethality—which is 
obviously among the most important metrics monitored 
in clinical trials—reported between diﬀ erent ﬁ lovirus 
disease outbreaks, treatment units, and times during 
outbreaks. Variability in lethality might also relate to 
factors such as time from disease onset to presentation 
for care, quality of care available, patient demographics, 
or variant of infecting virus.14,22–24 Accurate viral load 
measurement is also important in interpreting Ebola 
virus persistence in and transmission risk from immune-
privileged body compartments and ﬂ uids,25 including the 
male gonads or semen,25–28 eyes,29 CNS,30 breast milk,31 and 
the intrauterine space in pregnant women.32 Additionally, 
Ebola virus has occasionally been found in sweat and 
urine,33 and in atypical or asymptomatic cases.32 Similar 
reports note the persistence of Marburg virus in the eye,34 
semen,35 and breast milk,36 and in environmental samples. 
Viral load measurement could even be useful in assessing 
environmental decon tamination practices.37
Variability of ﬁ lovirus load determination
Viral load assay results are subject to substantial 
interassay, intra-assay, inter-run, and interindividual 
variability.38,39 Additionally, interpretation of viral load is 
further confounded by the fact that viral load does not 
necessarily correlate with viable replicating ﬁ lovirus.40 
Slight diﬀ erences between assays or genomic templates 
do not substantially aﬀ ect diagnostic performance under 
controlled conditions.41 However, in general, data 
gathered over a long period from multiple sites—eg, 
within and between laboratories—cannot be compared, 
because each site used distinct and speciﬁ c assays under 
variable conditions.42 For instance, a 1–2 log10 diﬀ erence 
in Ebola virus viral load, which may be within the margin 
of error of RT-PCR testing within and between many 
laboratories and assays, might correlate with signiﬁ cant 
diﬀ erences in lethality.10,12–14 Standard curves, generated 
by assessing multiple samples with known quantities of 
ﬁ loviral RNA, can be used to measure the variability of 
results and oﬀ er a better understanding of the meaning 
of results across laboratories and time points. However, 
standard curves have rarely been generated under 
outbreak conditions, probably because of the high 
numbers of samples processed and to obtain and provide 
results rapidly.
Several real-time RT-PCR tests for Ebola virus are 
commercially available. Eight of these tests recently 
received emergency use authorisation from the US Food 
and Drug Administration (FDA),43 and one received 
emergency use assessment and listing procedure from 
WHO,44 and are commonly used in the ﬁ eld for diagnostic 
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Ebola virus Glycoprotein Yes No Yes Yes† 1000–5000 PFU/mL NA 100% 100%
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Disease Control 
and Prevention
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Bioﬁ re Defense Ebola virus Unknown Yes No Yes No 10 000 PFU/mL 400 TCID50/mL45 87–92% 100%
FilmArray 
Biothreat-E Test



















Ebola virus RNA-dependent 
RNA polymerase
Yes No Yes No 4781 PFU/mL 1250 copies per mL46 97·8% 100%
Xpert Ebola 
Assay
Cepheid Ebola virus Glycoprotein + 
nucleoprotein
Yes Yes Yes No 232·4 copies per mL 
or 0·13–1 PFU/mL












EUA=emergency use authorisation. EUAL=emergency use assessment and listing. FDA=US Food and Drug Administration. NA=not applicable. PFU=plaque forming units. TCID50=50% tissue culture infectious 
dose. *Provided by the manufacturers. †Quantitative ability was established by the use of synthetic RNA standard curves but this feature is not part of the FDA EUA version. ‡Not part of EUAL approval from 
WHO, only mentioned in the manual of the manufacturer.
Table: Overview of RT-PCR assays for ﬁ loviruses and their status with the FDA and WHO
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requiring availability and testing of numerous 
predeﬁ ned standards, and is diﬃ  cult to implement 
under ﬁ eld conditions. A path forward might be gleaned 
from recent concerted international eﬀ orts to develop 
standardised quantitative assays and reference materials 
for other pathogens. For instance, high quality viral load 
clinical and analytical assessments are now possible for 
DNA and other RNA viruses.52,53 These assessments 
include three major commercial methods that are 
approved by the FDA for the measurement of HIV-1 
RNA in plasma: Amplicor Monitor, Versant HIV RNA 
Kit, and NucliSens HIV-1 QT System. The limits of 
detection for these assays range from 10–40 genome 
copies per mL.53 In the ﬁ eld of HIV/AIDS, viral load 
determination has become a routine test and is the basis 
of clinical patient management.54 Although the com-
mutability of some materials might need additional 
work to yield consensus,55 clearly these eﬀ orts have a 
positive eﬀ ect on comparability between assays.56 Eﬀ orts 
towards standardising ﬁ lovirus assays hold the promise 
of similar eﬀ ects and should be vigorously pursued.
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